This Study, by danish scientists, investigates the role of NGAL in predicting death and major adverse cardiovascular event (MACE).

The Study is published in the July 2012 edition of JACC (Journal of American College of Cardiology) The aim of this recent Study is to look into the prognostic value of NGAL (neutrophil gelatinase–associated lipocalin)  in a large population of patients with ST-segment elevation myocardial infarction (STEMI).

The Study was carried out in Denmark at Gentofte University Hospital, which is a fairly large hospital. GUH is a high-volume center where more than 1,500 PCIs are performed yearly.

Endpoints of the Study were all-cause mortality and major adverse cardiovascular events (MACE) defined as cardiovascular (CV) mortality or admission due to recurrent AMI or heart failure.

The conclusion is: High plasma NGAL independently predicts all-cause mortality and MACE in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.

The relationship between increased NGAL and AKI is also evident in the present study in which high NGAL is strongly associated with increased creatinine, reduced eGFR, and more frequent severe hemodynamic stress before admission and thus likely AKI.

Although the Study was carried out by danish scientists, The study was NOT using BioPorto’s The NGAL test, and BioPorto was not involved with the Study.

The abstract and much more is here:

http://content.onlinejacc.org/article.aspx?articleID=1217863

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years :)

 

What do you say?

Set your Twitter account name in your settings to use the TwitterBar Section.